Lannett Holdings, Inc. — the litigation-tracking name for Lannett Company, Inc. (NYSE: LCI until its delisting), a U.S. generic-drug manufacturer founded in 1942 as a Pennsylvania corporation and reincorporated in Delaware in 1991. Headquarters: Trevose, Pennsylvania (formerly Philadelphia). Lannett filed for Chapter 11 in 2023 and emerged under the seller entity Lannett Seller Holdco, Inc.; on June 29, 2026, Aurobindo Pharma USA Inc. (subsidiary of India's Aurobindo Pharma Limited) closed its acquisition of 100% of Lannett Company LLC for an enterprise value of about $250 million. Lannett is therefore now a private subsidiary of Aurobindo, not an independent public company.
Operations. Lannett develops, manufactures, packages and markets generic finished dosage forms — tablets, capsules, extended-release oral solids, topical, nasal and oral solutions — across roughly 100 product families, sold to wholesalers, distributors, chain pharmacies, mail-order pharmacies and government buyers. Its portfolio emphasizes non-opioid DEA-controlled substances, particularly ADHD therapeutics (e.g., amphetamine IR tablets, methylphenidate ER), generic liquids, and products such as levothyroxine, fluphenazine, posaconazole and sumatriptan, plus its NDA product Numbrino (cocaine hydrochloride nasal solution). Manufacturing is centered on a 425,000 sq ft cGMP plant in Seymour, Indiana, with capacity of about 3.6 billion doses annually. Reported net sales were $340.6 million in fiscal 2022 and about $306 million for the twelve months ended March 2025.
Litigation posture. Lannett is an operating company appearing exclusively as a defendant (0 plaintiff, 5 defendant entries) in U.S. patent litigation — the classic Hatch-Waxman ANDA-defendant profile, not an NPE. All tracked matters are venued in the District of New Jersey, a common forum for Paragraph IV pharmaceutical disputes, not a plaintiff-friendly NPE venue such as the Eastern District of Texas.
Notable cases. All five tracked records are Celgene Corporation v. Lannett Holdings, Inc., filed January 30, 2015 in D.N.J. (2:15-cv-00697) — evidently one action recorded multiple times. The suit followed Lannett's Paragraph IV ANDA for generic Thalomid (thalidomide); Lannett filed antitrust counterclaims, and the parties settled in October 2017 under a license permitting generic thalidomide launch on August 1, 2019.
Sources: lannett.com; Lannett FY2022 annual report/10-K; Aurobindo Pharma BSE disclosures (July 30, 2025; June 2026); Honigman press release; FiercePharma; CourtListener/Cigna complaint (D.N.J. 2:21-cv-00090).